» Articles » PMID: 24185585

Unmanipulated Haploidentical BMT Following Non-myeloablative Conditioning and Post-transplantation CY for Advanced Hodgkin's Lymphoma

Overview
Specialty General Surgery
Date 2013 Nov 5
PMID 24185585
Citations 55
Authors
Affiliations
Soon will be listed here.
Abstract

Twenty-six patients with advanced Hodgkin's disease received a related HLA haploidentical unmanipulated BMT, following a non-myeloablative conditioning with low-dose TBI, proposed by the Baltimore group; GvHD prophylaxis consisted of high-dose post-transplantation CY (PT-CY), mycophenolate and a calcineurin inhibitor. All patients had received a previous autograft, and 65% had active disease at the time of BMT. Sustained engraftment of donor cells occurred in 25 patients (96%), with a median time to neutrophil recovery (>0.5 × 10(9)/L) and platelet recovery (>20 × 10(9)/L) of +18 and +23 days from BMT. The incidence of grade II-IV acute GVHD and of chronic GVHD was 24% and 8%, respectively. With a median follow-up of 24 months (range 18-44) 21 patients are alive, 20 disease free. The cumulative incidence of TRM and relapse was 4% and 31%, respectively. The actuarial 3-year survival is 77%, the actuarial 3-year PFS is 63%. In conclusion, we confirm that high-dose PT-CY is effective as prophylaxis of GVHD after HLA haploidentical BMT, can prevent rejection and does not appear to eliminate the allogeneic graft versus lymphoma effect.

Citing Articles

Optimization of T-cell-replete haploidentical hematopoietic stem cell transplantation: the Chinese experience.

Mo X, Pei X, Huang X Haematologica. 2024; 110(3):562-575.

PMID: 39568419 PMC: 11873716. DOI: 10.3324/haematol.2024.286194.


Remission of relapsed/refractory classical Hodgkin lymphoma induced by brentuximab vedotin and pembrolizumab combination after allogeneic hematopoietic stem cell transplantation: a case report.

Giannotti F, de Ramon Ortiz C, Simonetta F, Morin S, Bernardi C, Masouridi-Levrat S Front Immunol. 2024; 15:1360275.

PMID: 38510239 PMC: 10950903. DOI: 10.3389/fimmu.2024.1360275.


Classical Hodgkin Lymphoma: From Past to Future-A Comprehensive Review of Pathophysiology and Therapeutic Advances.

Munir F, Hardit V, Sheikh I, Alqahtani S, He J, Cuglievan B Int J Mol Sci. 2023; 24(12).

PMID: 37373245 PMC: 10298672. DOI: 10.3390/ijms241210095.


Filling the Gap: The Immune Therapeutic Armamentarium for Relapsed/Refractory Hodgkin Lymphoma.

Leroyer E, Ziegler C, Moulin C, Campidelli A, Jacquet C, Rubio M J Clin Med. 2022; 11(21).

PMID: 36362802 PMC: 9656939. DOI: 10.3390/jcm11216574.


Immunomodulatory Effects of Bendamustine in Hematopoietic Cell Transplantation.

Stokes J, Molina M, Hoffman E, Simpson R, Katsanis E Cancers (Basel). 2021; 13(7).

PMID: 33916711 PMC: 8038415. DOI: 10.3390/cancers13071702.


References
1.
Linch D, Winfield D, Goldstone A, Moir D, Hancock B, McMillan A . Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet. 1993; 341(8852):1051-4. DOI: 10.1016/0140-6736(93)92411-l. View

2.
Gopal A, Metcalfe T, Gooley T, Pagel J, Petersdorf S, Bensinger W . High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: the Seattle experience. Cancer. 2008; 113(6):1344-50. PMC: 2700660. DOI: 10.1002/cncr.23715. View

3.
Peggs K, Hunter A, Chopra R, Parker A, Mahendra P, Milligan D . Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet. 2005; 365(9475):1934-41. DOI: 10.1016/S0140-6736(05)66659-7. View

4.
Sarina B, Castagna L, Farina L, Patriarca F, Benedetti F, Carella A . Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood. 2010; 115(18):3671-7. DOI: 10.1182/blood-2009-12-253856. View

5.
Peggs K, Kayani I, Edwards N, Kottaridis P, Goldstone A, Linch D . Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma. J Clin Oncol. 2011; 29(8):971-8. DOI: 10.1200/JCO.2010.32.1711. View